


HUMAN ANTIBODIES & HYBRIDOMAS 2007
THE 13TH INTERNATIONAL CONFERENCE



FINAL ORAL & POSTER PROGRAMS


The Thirteenth International Conference on


Human Antibodies & Hybridomas


HAH 2007 – 29-31 October 2007, Centro Congressi Palazzo Stelline, Milan, Italy


Scientific Advisory Committee


Local Organiser: Roberto Burioni (Universita Vita-Salute San Raffaele, Milan, Italy)
Keiji Koda (Tokyo University, Japan) · Peter Vollmers (University of Würzburg, Germany)
Mirek Gorny (New York University, USA) · Zdenka L. Janak (GlaxoSmithKline, USA)
David Humphreys (CellTech Group, Slough, UK) · Hakan Melstedt (Karolinska Institute, Sweden)
Kathy Potter (Southampton University, UK) · Jim Larrick (Panorama Research Inc., USA)
Alex van Gabain (InterCell AG, Vienna, Austria) · Alois Lang (Kenta Biotech, Switzerland)
Dee Athwal (To be confirmed)





















































Conference Program – Monday 29th October 2007

07.30am onwards

Registration

08.55-09.00

Opening Remarks

Mark Glassy – HAH 2007 Conference Chairman

08.00-08.10

'Welcome to Milano' from the HAH 2007 Local Organiser:
Roberto Burioni (University San Raffaele, Milan, Italy)

SESSION 1:

OPENING PLENARY SESSION

Moderator: Mark Glassy (RMRF, San Diego, California, USA)

08.10-10.00

'Antibodies and other scaffolds as a protein engineering challenge'
Andreas Plückthun (University of Zurich, Switzerland)

10.00-10.20

'Isolation of human monoclonal antibodies by mammalian cell display'
Martin Bachmann (Cytos Biotechnology, Zurich, Switzerland)

10.20-11.00

Coffee Break & Poster Set-Up

SESSION 2:

CANCER I

Moderators: Zdenka Janak (GSK, USA)
and Mark Glassy (RMRF, San Diego, USA)

11.00-11.30

'Reversible energy of surface IgM-mediated signalling in the two subsets of chronic lymphocytic leukaemia defined by immunoglobulin VH mutational status'
Kathleen N. Pottet, C. Ian Mockridge, Isla Wheatley, Louise A. Neville, Graham Packham and Freda Stevenson (University of Southampton, UK)

11.30-11.50

'Antibody-based cancer therapy through targeting metastasis, angiogenesis and immunosuppression factors'
Yan Wu (InClone Systems Inc., New York, USA)

11.50-12.10

'Targeting tumour vasculature using a novel antibody-IL-12 fusion protein'
Nigel Courtenay-Luck (Antisoma Research Ltd, London, UK)

12.10-12.30

'Development of IMC-1121B, a fully human antibody directed against vascular endothelial growth factor receptor 2 for anti-angiogenic therapy'
Zhenping Zhu (InClone Systems Incorporated, New York, USA)

12.30-12.50

'Adecatumab, a fully human EpCAM antibody in anti-tumour immunotherapy'
Tobias Raab (Micromet AG, Munich, Germany)

12.50-14.00

Lunch & Posters

SESSION 3:

CANCER II

Moderators: Peter Willmers (University of Wurzburg, Germany)
and Kathy Pitter (University of Southampton, UK)

14.00-14.30

'Title to be confirmed'
Zdenka K. Janak (GSK, King-of-Prussia, USA)

14.30-14.50

'Antibody-maytansinoid conjugates as anticancer therapeutics: proving their benefit'
John M. Lambert (Immunogen Inc., Cambridge, Massachusetts, USA)

14.50-15.10

'Blocking neuropilin-1 function phage antibodies has an additive effect with anti-VEGF to inhibit tumor growth'
Yan Wu (Genentech Inc., South San Francisco, California, USA)

15.10-15.25

'AFRA-SFM a new completely human antibody fragment for ovarian tumor targeting of radionuclides'
S. Canevari et al. (Istituto Nazionale dei Tumori, Milano, Italy)

15.25-15.40

'Induction of Neu5Gc-containing gangliosides related idiotypic networks in NSCLC patients immunized with an anti-idiotypic antibody'
Ana Maria Vazquez et al. (Centre of Molecular Immunology, Havana, Cuba)

15.40-16.00

Tea Break & Posters

SESSION 4:

MOLECULAR BIOLOGY I

Moderators: Jim W. Lamick (Panorama Research, USA)
and Sachdev Sidhu (Genentech Inc., USA)

16.00-16.30

'Insights into molecular recognition from minimalist synthetic antibodies'
Sachdev S. Sidhu (Genentech Inc., South San Francisco, California, USA)

16.30-16.50

'Human CD328 (FcγRIIB): A multifaceted target for enhanced antibody therapeutics'
Syd Johnson (MicroGenics Inc., Rockville, Maryland, USA)

16.50-17.10

'Humanization of a highly stable anti-lysozyme scFv endowed with intracellular functionality. A single framework residue dramatically affects protein expression and stability'
M. Donini, M.E. Vilani, V. Morea, V. Casali, R. Chiaraluce, A. Desiderio and E. Berveruto (INRA-Casaccia, Rome, Italy)

17.10-17.30

'Human antibodies selected by phage display as potent and selective protease inhibitors'
Sonia Schoonbroeck (Dyax S.A., Liege, Belgium)

Evening

HAH 2007 Welcome Reception & Poster Session

HAH 2007 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

Email: csumner@meetingsgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2007

Conference Program – Tuesday 30th October 2007SESSION 5:
ANTIBODY REPERTOIRE

Moderator: To be confirmed

09.00–09.45

KEYNOTE:

'Human B cell development: Immunization with influenza virus results in a rapid and profoundly clonal B cell response'

J. Donald Capra, Ken Smith, Patrick Wilson, Jens Vitzhammer and Rafi Ahmed (Oklahoma Medical Research Foundation, USA)

09.45–10.05

'Lessons learnt from nature. Immunoglobulin repertoire analysis and single chain Fv antibody libraries from B cells in breast carcinomas and melanomas'

Beatrix Kotlan, Michael McKnight, Andrea Ladanyi, Mepur H. Ravindranath, Erzsébet Ráso, József Toth, József Timar and Mark C. Glasby (National Medical Center, Budapest, Hungary)

10.05–10.25

'The molecular basis of autoreactive primary immunoglobulins'

Gary R. McLean, Chantal Cho and John W. Schrader (The University of Texas Medical School, Houston, Texas, USA)

10.25–10.45

'Identification and characterization of cynomolgus immunoglobulin constant'

Tanuja Arora (Amgen Inc, USA)

10.45–11.00

Coffee Break & Posters

SESSION 6:

CANCER III

Moderators: To be confirmed

11.00–11.30

'Monoclonal antibodies that mimic the T cell receptor and human disease'

Jon Weidanz (Receptor Logic Ltd, Amersville, Texas, USA)

11.30–12.00

'The human antibody SAM-6 defines a new tumour-specific variant of the heat shock protein GRP78'

S. Brandlein, N. Raaschert, L. Rasche, F. Hensel and H.P. Vollmers (University of Würzburg, Germany)

12.00–12.20

'De vitro and in vivo antitumor activities of anti HENV-K antibody against breast cancer'

F. Wang-Johanning, P. Yao, K. Rycal, J.B. Plummer, C. Wei and B.L. Johanning (UTMB, Anderson Cancer Center, Bastrop, Texas, USA)

12.20–12.40

'The 14F7, monoclonal antibody that mediates non-apoptotic cell death'

Dristina Mateo de Acosta et al. (Centre of Molecular Immunology, Havana, Cuba)

12.40–13.00

'Anti-ErbB2 human immunogens'

Claudia De Lorenzo and Giuseppe D'Alesio (University of Naples, Italy)

13.00–14.00

Lunch & Posters

SESSION 7:
INFECTIOUS DISEASES I

Moderator: Alois Lang (University of Bern, Switzerland)

14.00–14.45

'Human monoclonal against hepatitis C virus: a clinical perspective'
Roberto Burioni (University San Raffaele, Milan, Italy)

14.45–15.15

'Immunoglobulin gene usage for neutralizing human monoclonal antibodies directed against the V3 region of HIV-1'
Miroslaw K. Gorny, Xiao-Hong Wang, Coonstance Williams, Barbara Volny, Kathy Revesz, Tetsuya Kimura and Susan Zolla-Pozner (New York University School of Medicine, New York, USA)

15.15–15.35

'Antibodies mediating protection by a β -glucan conjugate vaccine and with direct fungicidal activity: the isotype makes a difference'
Antonella Torosantucci, Paola Chiari, Carlo Bromius and Antonia Cassone (ISS, Rome, Italy)

15.35–15.55

'Use of a novel hetero-hybridoma method to clone potent, high affinity human antibodies specific for botulinum neurotoxin'
Scott K. Dossain, Sharad P. Adekar, R. Mark Jones, M.D. Elias, Fetweli H. Al-Saleem, Michael J. Root and Lance L. Simpson (Thomas Jefferson University, Philadelphia, USA)

15.55–16.30

Tea & Posters

SESSION 8:
MOLECULAR BIOLOGY II

Moderator: To be confirmed

16.30–16.50

'Ribosome display for antibody engineering'

Ralph Minter (Cambridge Antibody Technology, Cambridge, UK)

16.50–17.10

'Generation of high antibody producing NSO cell lines by site-specific recombination'

Audrey Jia (Protein Design Labs Inc., Fremont, California, USA)

17.10–17.30

'RapMAT, a fast track for selecting high affinity HuCAL GOLD[®] antibodies'

Margit Urban (Morphosys AG, Martinsried, Germany)

17.30–17.50

'Antibody mammalian display system'

David Shen (Amgen Inc, USA)

17.50–18.10

'A new approach to antibody maturation through DNA destination in a retroviral system'

Mason Lu, Gareth T. Williams and Michael S. Neuberger (Tendex Inc, Houston Texas, USA)

Evening

Conference Dinner

Venue to be confirmed

HAH 2007 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom

Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516

Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2007

Conference Program – Wednesday 31st October 2007

SESSION 9: INFECTIOUS DISEASES II

Moderator: Roberto Baricci (University San Raffaele, Milan, Italy)

09.00-09.30

'Bacterial targets for anti-infective antibodies'
Eszter Nagy (Intercept/AB, Vienna, Austria)

09.30-09.50

'An influenza N1 neuraminidase-specific monoclonal antibody with broad inactivating activity against H5N1 viruses'
Vladislav Yusilov, Gene A. Palmer, Goran Cuzovic, Robert Narisone, Patricia de la Rosa, Yoko Shoji and Vadim Mett (Proscia/US, Newark, Delaware, USA)

09.50-10.10

'Development of fully human MAbs neutralizing pathogenic orthopoxviruses'
Nina Tikunova, Tatjana Yun, Ljudmila Shingarova, Viktoria Vorobina, Nikolai Barmotav, Vera Morozova, Eugeni Belanov, Mikhail Kirpichnikov and Aleksander Ilyichev (State Research Center of Virology & Biotechnology 'Vector', Novosibirsk Region, Russia)

10.10-10.30

Review Presentation
'Marked enhancement of weak neutralizing activities of IgG1 mAbs specific for tetanus toxin in vivo by the IgG4 mAbs with almost nonexistent neutralizing activity against the toxin'
Joe Chiba et al. (Toyo University of Science, Tokyo, Japan)

10.30-10.50

Coffee Break & Posters

SESSION 10: APPLIED TECHNOLOGIES I

Moderator: To be confirmed

10.50-11.35

KEYNOTE:
'Antibody targeting of stem cells'
Jim W. Larrick (Parsippany Research, Mountain View, California, USA)

11.35-11.55

'Development of recombinant polyclonal antibodies'
John Haunum (Synphagen A/S, Lyngby, Denmark)

11.55-12.15

'UniBody: A novel human antibody-based platform for immunotherapy'
Janine Schuurman, Tom Visk, Aran Labrijn, Wim Breeke, Patrick van Berkel, Jan O.J. van de Winkel and Paul W.H.J. Parren (Genmab, Utrecht, The Netherlands)

12.15-12.35

'Treatment of Experimental Autoimmune Myasthenia Gravis with Human IgG₁ anti-acetylcholine receptor competitor antibodies'
M.H. De Baets, M. Liesen, P. Martinez-Martinez (University of Maastricht, The Netherlands) and P. Parren (Genmab, Utrecht, The Netherlands)

12.35-12.55

'Modulation of bone density by antibodies to sclerostin'
Martyne Robinson (UCB-Celltech, Slough, Berkshire, UK)

12.55-14.00

Lunch & Posters

SESSION 11: APPLIED TECHNOLOGIES II

Moderator: To be confirmed

14.00-14.30

'Design and discovery of antibody biopharmaceuticals'
Daniel Lightwood (UCB-Celltech, Slough, Berkshire, UK)

14.30-14.45

'Characterization of a tumor-targeting human recombinant monoclonal antibody produced in plants'
M.E. Villari, M. Danini, B. Morgun, L. Pisoni, C. Bacci, A. Desiderio and E. Benvenuto (ENEA-Casaccia, Rome, Italy)

14.45-15.00

'A new technology for intact antigen-based and receptor-mediated generation of novel monoclonal antibodies'
M. Terada, M. Hirano, E. Watanabe, Y. Kaneko, T.X. Tseng and T. Matsuda (Me University, Japan)

15.00-15.20

'Generation of antibodies against native proteins by genetic immunization targeting cell-surface receptors, tumor biomarkers, viruses and bacterial toxins with potential for diagnostic and therapeutic antibodies'
J.A. Thompson (GENOVAC GmbH, Freiburg, Germany)

15.20-15.40

'Electrochemiluminescence immunoassay development and qualifications'
Larry Lu (Mugen Genome Sciences Inc., Rockville, Maryland, USA)

15.40-16.00

'B200 Cellular Detection System integration into the hybridoma screening process at GSK'
 Trevor Warran (GlaxoSmithKline, Stevenage, UK)

SESSION 12:

CLOSING PLENARY LECTURE

Moderator: Mark Glassy (JDRRF, San Diego, California, USA)

16.00-16.30

'HAH 2007 Conference Summary and The Way Forward'
J. Donald Capra (Oklahoma Medical Research Foundation, USA)

16.30

Closing Remarks
Mark Glassy – HAH 2007 Conference Chairman

Tea & Departure

This provisional oral/poster program is correct at the time of printing, however the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference program.

HAH 2007 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.a-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2007

Conference Program – Poster Session

'An optimised monoclonal anti-CD20 antibody with enhanced ADCC against tumor cells from B-CLL patients'
C. de Romeuf et al. (I/FB, Lille, France)

'Monoclonal antibodies in the diagnosis of peste des petits ruminants (PPR) virus infection'
Rabindra P. Singh (Indian Veterinary Research Institute, Uttar Pradesh, India)

'A photo-micrographic account of the sequential morphogenesis of hybridoma development'
William Simmons (University of Wolverhampton, UK)

'Chemiluminescence is a choice method in the preliminary stages of screening tail/heart bleeds and hybridomas in the development of monoclonal antibodies'
William Simmons (University of Wolverhampton, UK)

'Comparison of serum free medium and serum rich medium in hybridoma development at subcloning/isotyping phase and how it impacts on protein purification. Also a choice method of reducing use of animals in scientific experiments'
William Simmons (University of Wolverhampton, UK)

HAH 2007 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2007

Conference Program – Poster Session

Sponsors

The HAH 2007 Scientific Advisory Committee and the organizers would like to acknowledge the support of the following sponsors:



HAH 2007 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
 Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
 Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2007